3/20/2012

A biosensor technology that uses genetically engineered white blood cells to rapidly diagnose methicillin-resistant staphylococcus aureus is undergoing clinical tests, according to diagnostics company Innovative Biosensors. The BioFlash-Dx technology is based on B cells that bind to pathogens. The company obtained $1.5 million of a targeted $2.7 million financing round to develop its platform for the detection of infections and cardiovascular disease.

Full Story:
MedCityNews.com

Related Summaries